Galmed Pharmaceuticals今日宣布，其前列腺癌研究项目迎来了里程碑式的首次数据披露。实验结果显示，在针对前列腺癌的模型中，Aramchol与恩杂鲁胺（Xtandi®）联合使用时，癌细胞死亡率较单用恩杂鲁胺实现了令人瞩目的3至4倍提升。
这一突破性发现，标志着Aramchol在肿瘤学领域的潜力得到了初步验证。研究者观察到，这种联合疗法不仅显著增强了抗肿瘤活性，更在机制上展现出与现有标准治疗互补的独特优势。
尽管当前数据仍处于临床前阶段，但其所传递的信号无疑是积极的。Galmed公司强调，这些结果将为后续更深入的临床探索奠定坚实基础，并有望为前列腺癌患者开辟新的治疗路径。业界专家认为，若这一效应能在人体临床试验中得到复现，Aramchol或许能成为联合治疗策略中的关键一环，重塑晚期前列腺癌的治疗格局。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.